Hyperglycemia and Physical Impairment in Frail Hypertensive Older Adults

Antonella Pansini1,2†, Angela Lombardi3†, Maria Morgante1, Salvatore Frullone1, Anna Marro1, Mario Rizzo1,4, Giuseppe Boccalone1, Antonio De Luca4, Gaetano Santulli3 and Pasquale Mone1,3*

1 ASL Avellino, Avellino, Italy, 2 ASL Caserta, Caserta, Italy, 3 Department of Medicine, Einstein Institute for Aging Research, Einstein-Sina Diabetes Research Center, Fielescher Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, New York, NY, United States, 4 Campania University, Caserta, Italy, 5 ASL Napoli, Naples, Italy

Background: Frailty is a multidimensional condition typical of elders. Frail older adults have a high risk of functional decline, hospitalization, and mortality. Hypertension is one of the most common comorbidities in elders. Hyperglycemia (HG) is frequently observed in frail older adults, and represents an independent predictor of worst outcomes, with or without diabetes mellitus (DM). We aimed at investigating the impact of HG on physical impairment in frailty.

Methods: We studied consecutive older adults with frailty and hypertension at the ASL (local health unit of the Italian Ministry of Health) of Avellino, Italy, from March 2021 to September 2021. Exclusion criteria were: age <65 years, no frailty, no hypertension, left ventricular ejection fraction <25%, previous myocardial infarction, previous primary percutaneous coronary intervention and/or coronary artery bypass grafting. Blood glucose, Hb1Ac, and creatinine were measured in all patients. Physical frailty was assessed applying the Fried Criteria; we performed a 5-meter gait speed (5mGS) test in all patients.

Results: 149 frail hypertensive older adults were enrolled in the study, of which 82 had normoglycemia (NG), and 67 had HG. We observed a significantly slower 5mGS in the HG group compared to the NG group (0.52 ± 0.1 vs. 0.69 ± 0.06; p<0.001). Moreover, we found a strong and significant correlation between 5mGS and glycemia (r: 0.833; p<0.001). A multivariable linear regression analysis using 5mGS as a dependent variable revealed a significant independent association with glycemia (p<0.001) after adjusting for likely confounders.

Conclusions: HG drives physical impairment in frail hypertensive older adults independently of DM.

Keywords: aging, blood glucose, cognitive impairment, COPD, diabetes, elderly, gait speed, MoCA score
BACKGROUND

Frailty is a multidimensional condition typical of elders that determines physical decline. Frail older adults have a high risk of functional decline, hospitalization, and mortality (1–4). Hence, a careful geriatric evaluation is one of the best strategies to obtain an early diagnosis of physical impairment, and managing comorbidities and complications is fundamental to counteract it (5–11). Hypertension is one of the most common comorbidities in elders, affecting endothelial function, leading to oxidative stress, inflammation, and atherosclerosis (12–19).

Hyperglycemia (HG) is frequently observed in frail hypertensive older adults, and we and others have shown that it represents an independent predictor of worst outcomes, even if diabetes mellitus (DM) is not present (20–23). Indeed, HG drives inflammation and oxidative stress, leading to endothelial dysfunction, with a negative impact on frail patients (7, 24–28).

In this context, reaching and maintaining an optimal glycemic control may be crucial to reduce the incidence of functional decline and avoid complications (11, 29–32). On these grounds, we investigated the impact of HG on physical impairment in frail hypertensive older adults.

METHODS

We studied consecutive older adults with frailty and hypertension at the ASL (local health unit of the Italian Ministry of Health) of Avellino and Caserta, Italy, from March 2021 to September 2021.

Inclusion criteria were: Age ≥65 years; frailty; primary hypertension. Exclusion criteria were: Age <65 years; absence of frailty; secondary hypertension or absence of hypertension; previous myocardial infarction, left ventricular ejection fraction <25%, and previous cardiac revascularization.

HG was defined as blood glucose level ≥140 mg/dL according to previous investigations that evaluated HG in complex patients, both diabetic and non-diabetic (33–37), and following ADA recommendations, which refer to this value for hospitalized patients (38) and/or subjects with impaired glucose tolerance (39).

Hypertension was defined as systolic blood pressure (SBP) ≥140 mmHg and/or diastolic blood pressure (DBP) ≥90 mmHg on repeated measurements, or as a previously diagnosed hypertension (40). Blood samples to measure glycemia, HbA1c, hyperlipidemia, and creatinine were taken from all patients. The study was approved by the Campania Nord Ethical Committee. A written informed consent was signed by all patients.

Assessment of Physical Frailty

A diagnosis of frailty status was made according to the Fried Criteria, as we previously reported (19, 41):

- Weight loss (unintentional loss ≥4.5 kg in the past year);
- Weakness (handgrip strength in the lowest 20% quintile at baseline, adjusted for sex and body mass index);
- Exhaustion (poor endurance and energy, self-reported);

![Study flow diagram](image-url)
- Slowness (walking speed under the lowest quintile adjusted for sex and height);
- Low physical activity level (lowest quintile of kilocalories of physical activity during the past week).

Frailty was diagnosed with at least 3 criteria out of 5.

A 5-meter gait speed (5mGS) test was performed in all patients, as we previously described (42). 5mGS was advocated as a reliable measure of physical capacity in frail patients with cardiovascular diseases (43). Indeed, this test evaluates lower extremity muscle function, neurological and cardiopulmonary capacity (44, 45).

Statistical Analysis

Data are presented as mean ± SD or percentage. We developed a dispersion model using Pearson analysis to assess the correlation between glycemia and 5mGS. To explore the impact of comorbidities, we carried out a multivariable linear regression model with a 5mGS test as a dependent variable. All calculations were performed using the software Statistical Product and Service Solutions (SPSS) version 26.

RESULTS

We screened 189 frail hypertensive patients. Since 13 patients did not give their consent and 27 subjects did not meet inclusion criteria, 149 patients were enrolled in the study, of which 82 had normoglycemia (NG) and 67 had HG (Figure 1).

Patients were similar in age, BMI, sex distribution, and comorbidities (Table 1). We found a strong and significant correlation between 5mGS and glycemia (r: 0.833; 95% C.I.: -0.8766 to -0.7765; p<0.001) in all patients (Figure 2).

We observed a significantly slower 5mGS in the HG group compared to the NG group (0.52 ± 0.1 vs. 0.69 ± 0.06; p<0.001) (Figure 3). A multivariable linear regression analysis with 5mGS as a dependent variable (Table 2) confirmed the significant

**TABLE 1 | Clinical characteristics of the patients.**

|       | NG      | HG      |
|-------|---------|---------|
| N     | 82      | 67      |
| Sex (M/F) | 36/46  | 29/38  |
| Mean age (years) | 84.62 ± 6.1 | 84.48 ± 6.3 |
| BMI (kg/m²) | 27.7 ± 1.6 | 27.9 ± 1.6 |
| SBP (mmHg) | 116.7 ± 7.4 | 119.0 ± 7.8 |
| DBP (mmHg) | 79.6 ± 6.7 | 79.4 ± 6.3 |
| Heart rate (bpm) | 87.3 ± 9.8 | 87.1 ± 8.8 |
| 5mGS (m/s) | 0.69 ± 0.06 | 0.52 ± 0.1* |
| Comorbidities, n (%) | | |
| Diabetes | 32 (39.0) | 54 (80.6)* |
| COPD | 38 (46.3) | 33 (49.3) |
| CKD | 39 (47.6) | 35 (52.2) |
| CVD | 44 (53.7) | 34 (50.7) |
| Hyperlipidemia | 43 (52.4) | 37 (55.2) |
| Laboratory analyses | | |
| Plasma glucose (mg/dl) | 100.1 ± 19.6 | 231.5 ± 71.4* |
| HbA1c, mmol/mol (%) | 57 ± 5.5 (7.4 ± 0.5) | 58 ± 5.5 (7.5 ± 0.5) |
| Serum creatinine (mg/dl) | 1.1 ± 0.5 | 1.2 ± 0.5 |
| Global Cognitive Evaluation | | |
| MoCA | 19.5 ± 3.6 | 19.1 ± 3.9 |

Data are means ± SD or n (%). 5mGS, 5 m gait speed; BMI, body mass index; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CVD, cerebrovascular disease; DBP, diastolic blood pressure; HbA1c, glycosylated hemoglobin; HF, heart failure; HG, hyperglycemic; MoCA, Montreal Cognitive Assessment; NG, normoglycemic; SBP, systolic blood pressure. *p < 0.001.
impact of glycemia (p<0.001) and revealed also an association with COPD (p: 0.043).

DISCUSSION

Our study indicates that frail hypertensive elders with HG have a significantly lower 5mGS compared to NG subjects. It is important to emphasize the fact that these results refer to a frail hypertensive population of older adults, in which physical performance affects functional decline, loss of independence, and cognitive impairment (30, 46).

Glucose levels may increase the risk of frailty in older adults without DM (31). It is interesting to observe that these findings are independent of a previous diagnosis of DM as well as from HbA1c values. In this scenario, HG drives physical impairment independently of DM and we speculate that glycemic control appears to be the best way to attempt to reverse physical impairment, with or without DM.

Our study does have some limitations. First, the study population is relatively small; second, there is no follow-up. Therefore, further studies are necessary to confirm our results, ideally in large randomized trials. We also reckon that a majority of our study population is represented by women; this finding is in agreement with the REPOSI Study on elderly people (47). Consistent with our observations, HG is associated with the development of frailty and lower extremity mobility limitations in older women (48, 49). Furthermore, a previous study had suggested to consider functionally independent women with osteoporosis and arthritis as a different cluster of frailty (50).

CONCLUSIONS

Taken together, our data indicate that HG drives physical impairment in frail and hypertensive older adults independently from DM and HbA1c values.
40. American Diabetes Association. Classification and Diagnosis of Diabetes. Diabetes Care (2017) 40:S11–24. doi: 10.2337/dc17-S005
41. Unger T, Borghi C, Charchar F, Khan NA, Pouleur NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension (2020) 75:1334–57. doi: 10.1161/HYPERTENSIONAHA.120.15026
42. Mone P, Pansini A, Jankauskas SS, Varzideh F, Kansakar U, Lombardi A, et al. L-Arginine Improves Cognitive Impairment in Hypertensive Frail Older Adults. Front Cardiovasc Med (2022). in press.
43. Alfilalo J, Alexander KP, Mack MJ, Maurer MS, Green P, Allen LA, et al. Frailty Assessment in the Cardiovascular Care of Older Adults. J Am Coll Cardiol (2014) 63:747–62. doi: 10.1016/j.jacc.2013.09.070
44. Studenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait Speed and Survival in Older Adults. JAMA (2011) 305:50–8. doi: 10.1001/ jama.2010.1923
45. Mone P, Lombardi A, Gambardella J, Pansini A, Macina G, Morgante M, et al. Empagliflozin Improves Cognitive Impairment in Frail Older Adults with Type 2 Diabetes and Heart Failure with Preserved Ejection Fraction. Diabetes Care. (2022) In press. doi: 10.2337/dc21-2434
46. Lee JS, Auyeung TW, Leung J, Kwok T, Leung PC, Woo J. Physical Frailty in Older Adults Is Associated With Metabolic and Atherosclerotic Risk Factors and Cognitive Impairment Independent of Muscle Mass. J Nutr Health Aging (2011) 15:857–62. doi: 10.1007/s12603-011-0134-1
47. Corrao S, Santalucia P, Argano C, Djade CD, Barone E, Tettamanti M, et al. Gender-Differences in Disease Distribution and Outcome in Hospitalized Elderly: Data From the REPOSI Study. Eur J Intern Med (2014) 25:617–23. doi: 10.1016/j.ejim.2014.06.027
48. Blaum CS, Xue QL, Tian J, Semba RD, Fried LP, Walston J. Is Hyperglycemia Associated With Frailty Status in Older Women? J Am Geriatr Soc (2009) 57:840–7. doi: 10.1111/j.1532-5415.2009.02196.x
49. Kalyani RR, Tian J, Xue QL, Walston J, Cappola AR, Fried LP, et al. Hyperglycemia and Incidence of Frailty and Lower Extremity Mobility Limitations in Older Women. J Am Geriatr Soc (2012) 60:1701–7. doi: 10.1111/ j.1532-5415.2012.04099.x
50. Marcucci M, Franchi C, Nobili A, Mannucci PM, Ardoino I. Defining Aging Phenotypes and Related Outcomes: Clues to Recognize Frailty in Hospitalized Older Patients. J Gerontol A Biol Sci Med Sci (2017) 72:395–402. doi: 10.1093/ gerona/glw188

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Pansini, Lombardi, Morgante, Frullone, Marro, Rizzo, Martinelli, Boccalone, Santulli and Mone. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.